All product descriptions and articles provided on this website are intended strictly for informational and educational purposes. Our products are designed exclusively for in-vitro research (i.e., experiments conducted outside of a living organism, typically in glassware such as test tubes or petri dishes). These compounds are not approved by the FDA for use in humans or animals. They are not medications, nor are they intended to diagnose, treat, prevent, or cure any disease or medical condition. Any bodily administration-human or animal-is strictly prohibited by law. Our products are not for human consumption under any circumstances.
Short answer: no peptide is approved for peripheral neuropathy, and only one — ARA-290 — has been tested in people. ARA-290 (cibinetide), an 11-amino-acid fragment derived from erythropoietin, is the single compound on the usual “peptides for nerve damage” lists with published, placebo-controlled human data in small-fibre and diabetic neuropathy. Everything else stops at rodent stage.
That includes the two most often recommended: TB-500 / Thymosin Beta-4 and BPC-157. Their nerve evidence comes from sciatic nerve crush and transection models and from chemically induced diabetic neuropathy in rats — real published work, but animal work, with no human neuropathy trial behind it.
This page sorts the compounds by what was measured and in which species, not by how promising they sound. Prime Lab does not sell ARA-290; it is listed first anyway, because leaving it out would turn an evidence review into a catalogue. Every compound discussed is supplied for research use only.
Which Peptides for Neuropathy Have Human Data
TB-500 supports nerve repair by improving blood flow, reducing inflammation, and restoring function. Preclinical studies[2] in diabetic mice show that it increases sciatic nerve vascular density and improves conduction velocity, both markers of healthy nerve activity. It stimulates angiogenesis to supply oxygen and nutrients vital for regeneration. Moreover, TB-500 reduces inflammation, targeting both vascular dysfunction and cellular pathways needed for recovery. Its impact is clear through several key mechanisms:
- Increases new blood vessel growth to restore impaired circulation
- Suppresses inflammatory responses that contribute to nerve injury
- Repairs neurovascular function and supports nerve fiber regeneration
These functions work together to create a favorable environment for healing peripheral nerves. TB-500's ability to act on both vascular and nerve cells positions it as a promising candidate for treating neuropathies caused by diabetes and other conditions.
How TB-500 Is Proposed to Repair Nerve Tissue
The Angiopoietin/Tie2 pathway is a critical molecular mechanism through which TB-500 promotes nerve and vascular repair. This signaling axis regulates the stability and function of blood vessels, which are essential for nerve health and regeneration.
To understand how TB-500 works, let’s break down its influence on key components of this pathway.
Role of Ang1 and Ang2
Angiopoietin-1 (Ang1) acts as a stabilizer and maturer of blood vessels by binding to its receptor Tie2 on endothelial cells. In contrast, Angiopoietin-2 (Ang2) typically disrupts this stability, especially during disease, by competing with Ang1 and destabilizing vessels. Diabetes increases Ang2 and decreases Ang1, worsening nerve vascular function.
TB-500’s Mechanism Through PI3K/Akt
TB-500 reverses these diabetic changes[3] by boosting Ang1 while lowering Ang2 levels. It activates the PI3K/Akt signaling pathway in both endothelial and Schwann cells, restoring vascular balance. As a result, blood vessel formation improves, which supports enhanced nerve conduction velocity and better sensory function, as demonstrated in diabetic mouse models.
What the Animal Studies Actually Measured
Animal studies show that thymosin beta-4 and TB-500 can restore nerve function in diabetic neuropathy. In one major study[4], diabetic mice treated with thymosin beta-4 showed a 35% increase in nerve conduction velocity and higher sciatic nerve blood flow within four weeks compared to saline controls. The peptide also normalized angiopoietin-1 and reduced angiopoietin-2, improving vascular integrity around nerves.
Extended treatment protected axons and myelin sheaths from degeneration and increased intraepidermal nerve fiber density by up to 25%. These effects improved thermal latency and mechanical response, confirming functional recovery. Mechanistically, TB-500 activates the PI3K/Akt signaling pathway. This pathway promotes angiogenesis, stabilizes endothelial cells, and enhances Schwann cell activity to support long-term repair.
How Long Nerve Repair Studies Run — and What They Showed
TB-500 shows strong potential for supporting nerve regeneration in humans, as preclinical research highlights[5] its roles in wound healing, angiogenesis, and inflammation control. However, no large clinical trials have yet confirmed its direct effectiveness in treating neuropathy. Here are the most important findings to consider:
- TB-500 promotes the formation of new blood vessels and enhances tissue repair, which are critical for nerve regeneration following injury or disease.
- Researchers speculate it could aid not only diabetic neuropathy but also nerve damage from trauma or chemotherapy, thanks to its broad regenerative and anti-inflammatory effects.
- Its anti-inflammatory properties may help reduce fibrosis, a common barrier to nerve recovery in chronic neuropathy.
- Most current evidence derives from rodent studies[6] showing improved nerve conduction velocity and sensory function after peptide treatment.
Side Effects and What Is Still Unknown
Currently, TB-500 is not FDA-approved for any human use; it remains strictly a research peptide. Regulatory oversight is tight, and there is a lack of rigorous safety data from human trials. Researchers emphasize the importance of controlled, blinded clinical studies before making clinical recommendations[7]. Moreover, the variability of peptide dosing and purity in uncontrolled contexts adds further risk and complexity for translational research.
Despite these challenges, preclinical results warrant further investigation, especially given TB-500’s strong safety profile in animal trials and broad mechanisms of action. Long-term administration in diabetic mice has not shown significant adverse side effects, either on blood glucose or body weight, under controlled experimental conditions.
Evidence Summary: Which Compound Has the Strongest Data
Peripheral neuropathy presents significant challenges, including nerve damage, reduced function, and limited effective therapies. Researchers face difficulties in reversing neurovascular dysfunction and improving nerve conduction, which limits treatment outcomes. The lack of precise regenerative options drives continued investigation into peptides like TB-500 that target both vascular and neuronal repair mechanisms.
Prime Lab Peptides offers high-purity, rigorously tested TB-500 to support cutting-edge research in neuropathy and regenerative medicine. Our products enable researchers to explore novel therapeutic avenues with confidence. By partnering with Prime Lab Peptides, scientists gain access to premium peptides designed to accelerate discovery and translate findings into impactful treatments for neuropathic conditions.
Compounds Referenced in This Review
- TB-500 – 5mg — the Thymosin Beta-4 fragment used in the rodent nerve and diabetic neuropathy models described above.
- BPC-157 – 10mg — studied in rat sciatic nerve crush and transection models.
- BPC-157 / TB-500 – 5mg / 5mg — the paired format; the two have been combined in soft-tissue repair work, not in neuropathy studies.
- Semax – 5mg — BDNF-linked and studied in central nervous system models rather than peripheral nerve.
ARA-290 (cibinetide), the only compound in this review with published human neuropathy trials, is not part of the Prime Lab catalogue.
Why Spinal Cord Injury Is a Harder Repair Problem Than Peripheral Neuropathy
The two injuries fail in different ways, which is why a result in one does not carry over to the other. In a peripheral nerve, Schwann cells survive the insult, clear debris and form guidance tubes that a severed axon can grow back along — slowly and imperfectly, but it happens. In the spinal cord that scaffolding is absent, and several mechanisms actively work against regrowth:
- Astrocytes seal the lesion with a dense scar that blocks axonal extension both mechanically and chemically.
- Oligodendrocytes die, and the myelin debris they leave behind carries growth-inhibitory signals.
- A secondary injury cascade — inflammation, oxidative stress, edema — kills cells that survived the initial trauma over the following days.
- The lesion frequently resolves into a fluid-filled cavity rather than repaired tissue.
The NIH estimates roughly 18,000 new spinal cord injuries a year in the United States, and standard care remains stabilisation and symptom management rather than regeneration.
This matters directly for how the peripheral neuropathy evidence above should be read. An improvement in sciatic nerve conduction velocity in a diabetic rodent does not transfer to a cord lesion. The problem the peptide addressed in that model — impaired perfusion and an Ang1/Ang2 imbalance around the nerve — is not the problem that stops an axon from crossing a glial scar. Any claim about spinal cord regeneration has to rest on spinal cord experiments, which are a separate and much thinner body of work.
What the Spinal Cord Studies Measured — and in Which Model
A single in vivo rodent study carries most of the weight. Cheng and colleagues (2014, Neuropharmacology) gave rats thymosin β4 or saline by intraperitoneal injection after a mild compression injury of the cord. At seven days post-injury, the treated animals differed from saline controls on the following measures:
- Locomotor scores on the Basso-Beattie-Bresnahan scale and on footprint analysis were improved.
- Counts of surviving neurons and oligodendrocytes were higher.
- Myelin basic protein, a marker of mature oligodendrocytes, was 57.8% higher.
- ED1, a marker of activated microglia and macrophages, was 36.9% lower; IL-10 mRNA rose and pro-inflammatory cytokine gene expression fell.
- The lesion cavity bounded by the astrocyte scar was smaller.
Alongside it, Li and colleagues (2019, Gene) worked in vitro: rat spinal-cord-derived neural stem/progenitor cells exposed to hydrogen peroxide showed higher viability and less apoptosis, reactive oxygen species and cytokine release when thymosin β4 was added, with TLR4 and MyD88 expression falling. Cells in a dish, not an injured animal.
Two caveats circulate as though they were data. The frequently cited Xiong 2012 paper in the Annals of the New York Academy of Sciences is a review arguing thymosin β4 as a candidate for traumatic brain injury — not an original spinal cord experiment. And all of this work used full-length thymosin β4; TB-500 is a fragment of it, and the two are treated as interchangeable without that equivalence having been tested in a cord model. No human spinal cord injury trial of either has been published.
TB-500 With BPC-157: Does Combining Them Add Anything?
In the one published experiment that tested the combination against each peptide alone, it did not. Biçer and colleagues (2026, Joint Diseases and Related Surgery) transected and repaired the Achilles tendon in 32 rats, then split them into four groups: control, BPC-157, TB-500, and both peptides together, dosed intraperitoneally for four weeks. TB-500 alone reached statistical significance on maximum load to failure and on the Bonar histological score. The combination group improved the Movin score relative to controls but did not outperform either peptide given on its own. The authors read this as possible convergence on shared downstream pathways, and explicitly flag it as a hypothesis awaiting confirmation.
Two limits on how far that finding travels: it is a tendon rather than nerve tissue, and it is a single exploratory study in a small number of animals.
For the cord itself, BPC-157 has its own separate rodent literature. Perović and colleagues (2019) reported preserved axons and motoneurons, resolved spasticity and improved tail motor function in rats after a compression injury, with EMG and histology followed out to a year. It was administered alone.
No published study has co-administered TB-500 and BPC-157 in a spinal cord or peripheral nerve model. The synergy framing that travels with the paired format is an extrapolation from separate single-agent results, not something anyone has measured in nerve tissue.
FAQs
What is TB-500, and how does it support nerve repair?
TB-500 is a synthetic peptide derived from Thymosin Beta-4. It promotes angiogenesis to support new blood vessel growth. It also reduces inflammation and enhances cell migration. Together, these actions create conditions that favor vascular stability and nerve regeneration in research models.
Has TB-500 been tested for treating peripheral neuropathy?
Preclinical studies in diabetic mice show that TB-500 improves nerve conduction velocity and blood flow. These results suggest a possible value for peripheral neuropathy recovery. However, more clinical research is needed to confirm its benefits in humans.
Is TB-500 approved for human use in neuropathy treatment?
TB-500 is not FDA-approved for neuropathy or any human therapeutic use. It remains classified as a research peptide under investigation, with no confirmed clinical applications established in human nerve-related conditions.
Why choose Prime Lab Peptides for TB-500 research?
Prime Lab Peptides provides high-purity TB-500 peptides that are rigorously tested. Moreover, we follow strict quality standards to ensure reliable and consistent results. Therefore, this makes us a trusted partner for researchers exploring TB-500’s role in neuropathy and nerve repair.
References
